Drug Recall: Sucralfate Tablets (Nostrum Laboratories) for Ulcers
Nostrum Laboratories issued a nationwide recall of all sucralfate 1 gram tablets. The company has shut down all operations following its bankruptcy filing in September 2024. As a result, Nostrum can no longer guarantee the quality, strength, or purity of the drug for the remainder of its shelf life. The recall covers all lots manufactured after June 2023 that have not yet expired.
Sucralfate is prescribed short-term (up to 8 weeks) for peptic ulcers and is a generic for brand name Carafate. There have been no reported adverse events related to this recall to date. Nostrum is not accepting returns and instructs that all recalled product be destroyed. Patients and healthcare providers are advised to discontinue use immediately and report any adverse effects to the FDA’s MedWatch program
FDA Consumer Recall Announcement (July 11) and
FDA Enforcement Report
Read or add patient reviews of Sucralfate (or Carafate).
Drug Recall: Levothyroxine Tablets
Accord Healthcare is recalling more than 150,000 bottles of levothyroxine tablets in strengths ranging from 25 mcg to 175 mcg because the drugs were found to be subpotent, with assay results below the approved specification. The drug was manufactured by Intas Pharmaceuticals in India. Levothyroxine treats hypothyroidism and is generic for Synthroid. The subpotent products may not provide adequate treatment for thyroid disorders. Patients affected should consult their healthcare provider about obtaining replacement medication and monitoring thyroid levels. This recall was classified as a Class II recall by the FDA on July 14.
Recall Announcement
Drug Recall: Gabapentin 100mg capsules
The Harvard Drug Group’s Major Pharmaceuticals is recalling more than 25,000 packages of Gabapentin 100 mg capsules due to defective blister packaging that may be inadequately sealed. The capsules were packaged and distributed by Major Pharmaceuticals in Indianapolis, Indiana, with an expiration date of October 2026. The U.S. FDA classified this recall as Class II in July 2025. Patients and pharmacies possessing the affected lots should consult their pharmacist or healthcare provider for guidance. Gabapentin prevents and controls seizures. It is also used to relieve nerve pain following shingles.This recall was classified as a Class II recall by the FDA on July 25, 2025.
Recall Announcement (enforcement report)
Read or add patient reviews for
gabapentin.